PharmaBlock Sciences (Nanjing), Inc.

Shenzhen Stock Exchange 300725.SZ

PharmaBlock Sciences (Nanjing), Inc. Shareholders' Equity for the year ending December 31, 2023: USD 398.93 M

PharmaBlock Sciences (Nanjing), Inc. Shareholders' Equity is USD 398.93 M for the year ending December 31, 2023, a 3.59% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

PharmaBlock Sciences (Nanjing), Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 385.12 M, a 0.81% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 382.03 M, a 31.61% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 290.27 M, a 172.84% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 106.39 M, a 22.00% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Shenzhen Stock Exchange: 300725.SZ

PharmaBlock Sciences (Nanjing), Inc.

CEO	Dr. Minmin Yang Ph.D.
IPO Date	Nov. 10, 2017
Location	China
Headquarters	10 Xuefu Road
Employees	2,455
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Petrochemicals

Description

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years